Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Colman

Showing results (121-130 of 155) with videos related to

Pageof 16
Sort By:
Neuro-Oncology|May 3, 2015
Toward precision medicine in glioblastoma: the promise and the challengesMichael D Prados, Sara A Byron, Nhan L Tran, et al.
The New England Journal of Medicine|February 21, 2014
A randomized trial of bevacizumab for newly diagnosed glioblastomaMark R Gilbert, James J Dignam, Terri S Armstrong, et al.
Neuro-Oncology Advances|April 24, 2026
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trialByram H Ozer, Adam L Cohen, Howard Colman, et al.
Molecular Cancer Therapeutics|August 16, 2020
Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen TherapyChristian K Werner, Uchechi J Nna, Hanshi Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2021
Designing Clinical Trials for Combination Immunotherapy: A Framework for GlioblastomaKirit Singh, Kristen A Batich, Patrick Y Wen, et al.
Neuro-Oncology|April 5, 2022
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumorsBenjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, et al.
Neuro-Oncology|September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastomaMarta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2025
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 AstrocytomaHoward Colman, Giuseppe Lombardi, Eric T Wong, et al.
Neurosurgery|June 20, 2019
Letter: When Less is More: Dexamethasone Dosing for Brain TumorsMary Jane Lim-Fat, Wenya Linda Bi, Janet Lo, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 13, 2015
Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic ImpactPratheesh Sathyan, Pascal O Zinn, Anantha L Marisetty, et al.
Pageof 16

Showing results (121-130 of 155) with videos related to

Sort By:
Pageof 16
Neuro-Oncology|May 3, 2015
Toward precision medicine in glioblastoma: the promise and the challengesMichael D Prados, Sara A Byron, Nhan L Tran, et al.
The New England Journal of Medicine|February 21, 2014
A randomized trial of bevacizumab for newly diagnosed glioblastomaMark R Gilbert, James J Dignam, Terri S Armstrong, et al.
Neuro-Oncology Advances|April 24, 2026
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trialByram H Ozer, Adam L Cohen, Howard Colman, et al.
Molecular Cancer Therapeutics|August 16, 2020
Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen TherapyChristian K Werner, Uchechi J Nna, Hanshi Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2021
Designing Clinical Trials for Combination Immunotherapy: A Framework for GlioblastomaKirit Singh, Kristen A Batich, Patrick Y Wen, et al.
Neuro-Oncology|April 5, 2022
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumorsBenjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, et al.
Neuro-Oncology|September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastomaMarta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2025
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 AstrocytomaHoward Colman, Giuseppe Lombardi, Eric T Wong, et al.
Neurosurgery|June 20, 2019
Letter: When Less is More: Dexamethasone Dosing for Brain TumorsMary Jane Lim-Fat, Wenya Linda Bi, Janet Lo, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 13, 2015
Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic ImpactPratheesh Sathyan, Pascal O Zinn, Anantha L Marisetty, et al.
Pageof 16